 John Meshki
Concepts (137)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Substance P | 7 | 2016 | 44 | 0.800 |
Why?
| | Receptors, Neurokinin-1 | 5 | 2013 | 12 | 0.660 |
Why?
| | Cell Membrane | 3 | 2012 | 670 | 0.620 |
Why?
| | p21-Activated Kinases | 1 | 2011 | 14 | 0.380 |
Why?
| | Protein Kinase C-epsilon | 2 | 2010 | 27 | 0.370 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2010 | 145 | 0.340 |
Why?
| | rho-Associated Kinases | 2 | 2012 | 80 | 0.330 |
Why?
| | Receptors, Purinergic P2 | 2 | 2005 | 19 | 0.280 |
Why?
| | Neutrophils | 4 | 2005 | 1089 | 0.280 |
Why?
| | Prostatic Neoplasms | 2 | 2010 | 913 | 0.250 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2010 | 1128 | 0.240 |
Why?
| | Uridine Triphosphate | 2 | 2005 | 11 | 0.240 |
Why?
| | Neurokinin-1 Receptor Antagonists | 4 | 2013 | 9 | 0.230 |
Why?
| | Cell Degranulation | 1 | 2003 | 39 | 0.220 |
Why?
| | Signal Transduction | 10 | 2013 | 4501 | 0.220 |
Why?
| | Phosphorylation | 5 | 2011 | 1558 | 0.220 |
Why?
| | HIV-1 | 3 | 2014 | 768 | 0.210 |
Why?
| | Adenosine Triphosphate | 2 | 2005 | 428 | 0.200 |
Why?
| | Calcium | 8 | 2013 | 1089 | 0.200 |
Why?
| | Cell Line | 4 | 2013 | 2629 | 0.150 |
Why?
| | Morpholines | 3 | 2013 | 102 | 0.140 |
Why?
| | Neurotransmitter Agents | 2 | 2014 | 75 | 0.130 |
Why?
| | Apoptosis | 4 | 2010 | 2349 | 0.130 |
Why?
| | Monocytes | 2 | 2016 | 503 | 0.130 |
Why?
| | Protein Kinase C | 2 | 2009 | 271 | 0.130 |
Why?
| | Chemokines | 1 | 2016 | 215 | 0.120 |
Why?
| | Cell Line, Tumor | 3 | 2011 | 2698 | 0.120 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 1 | 2014 | 53 | 0.110 |
Why?
| | Somatostatin | 1 | 2013 | 52 | 0.110 |
Why?
| | Macrophages | 3 | 2016 | 1259 | 0.110 |
Why?
| | Fibrinogen | 2 | 2004 | 143 | 0.110 |
Why?
| | Antigens, CD | 2 | 2014 | 440 | 0.110 |
Why?
| | Cell Movement | 1 | 2016 | 863 | 0.100 |
Why?
| | Receptors, Cell Surface | 1 | 2014 | 350 | 0.100 |
Why?
| | Analgesics | 1 | 2013 | 156 | 0.100 |
Why?
| | Colchicine | 1 | 2011 | 24 | 0.100 |
Why?
| | Cell-Derived Microparticles | 1 | 2012 | 56 | 0.100 |
Why?
| | Microscopy, Video | 1 | 2011 | 26 | 0.100 |
Why?
| | Blotting, Western | 2 | 2011 | 1143 | 0.090 |
Why?
| | bcl-Associated Death Protein | 1 | 2010 | 5 | 0.090 |
Why?
| | Tubulin | 1 | 2011 | 122 | 0.090 |
Why?
| | Microscopy, Confocal | 1 | 2011 | 304 | 0.090 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 2010 | 151 | 0.090 |
Why?
| | Central Nervous System Diseases | 1 | 2010 | 60 | 0.090 |
Why?
| | Green Fluorescent Proteins | 1 | 2011 | 370 | 0.080 |
Why?
| | Cell Survival | 2 | 2010 | 1014 | 0.080 |
Why?
| | Actins | 1 | 2011 | 376 | 0.080 |
Why?
| | Myosin-Light-Chain Phosphatase | 1 | 2009 | 3 | 0.080 |
Why?
| | Myosin Light Chains | 1 | 2009 | 26 | 0.080 |
Why?
| | Cell Shape | 1 | 2009 | 54 | 0.080 |
Why?
| | Intracellular Space | 1 | 2009 | 68 | 0.080 |
Why?
| | rho GTP-Binding Proteins | 1 | 2009 | 61 | 0.080 |
Why?
| | HIV Infections | 2 | 2014 | 2453 | 0.080 |
Why?
| | Microscopy, Electron | 1 | 2009 | 408 | 0.080 |
Why?
| | Mitogen-Activated Protein Kinases | 3 | 2004 | 269 | 0.080 |
Why?
| | Gene Expression Regulation | 2 | 2014 | 2321 | 0.070 |
Why?
| | Cellular Senescence | 1 | 2009 | 151 | 0.070 |
Why?
| | Receptors, Purinergic P2Y2 | 2 | 2005 | 5 | 0.070 |
Why?
| | Cytoplasmic Granules | 2 | 2004 | 81 | 0.070 |
Why?
| | Pancreatic Elastase | 2 | 2004 | 55 | 0.070 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2009 | 307 | 0.070 |
Why?
| | Brain | 2 | 2016 | 2355 | 0.060 |
Why?
| | Neurons | 1 | 2013 | 1277 | 0.060 |
Why?
| | Humans | 14 | 2016 | 114043 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2013 | 1836 | 0.060 |
Why?
| | Chemokine CCL2 | 2 | 2016 | 104 | 0.060 |
Why?
| | Anti-HIV Agents | 1 | 2010 | 663 | 0.060 |
Why?
| | Nucleotides | 1 | 2005 | 112 | 0.060 |
Why?
| | Membrane Microdomains | 1 | 2003 | 31 | 0.060 |
Why?
| | Butadienes | 1 | 2003 | 30 | 0.060 |
Why?
| | Lipoxygenase Inhibitors | 1 | 2003 | 36 | 0.060 |
Why?
| | Enzyme Inhibitors | 2 | 2004 | 743 | 0.060 |
Why?
| | beta-Cyclodextrins | 1 | 2003 | 28 | 0.060 |
Why?
| | Protein Kinase Inhibitors | 1 | 2009 | 784 | 0.050 |
Why?
| | Blood-Brain Barrier | 2 | 2016 | 106 | 0.050 |
Why?
| | Membrane Lipids | 1 | 2003 | 87 | 0.050 |
Why?
| | Nitriles | 1 | 2003 | 149 | 0.050 |
Why?
| | Imidazoles | 1 | 2003 | 203 | 0.050 |
Why?
| | Enzyme Activation | 1 | 2003 | 771 | 0.050 |
Why?
| | Indoles | 1 | 2003 | 300 | 0.050 |
Why?
| | Drug Interactions | 2 | 2013 | 337 | 0.040 |
Why?
| | Pyrazoles | 1 | 2003 | 361 | 0.040 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2005 | 1142 | 0.040 |
Why?
| | Pyridines | 1 | 2003 | 419 | 0.040 |
Why?
| | Aging | 1 | 2009 | 1611 | 0.040 |
Why?
| | Up-Regulation | 2 | 2016 | 802 | 0.040 |
Why?
| | Culture Media, Conditioned | 1 | 2016 | 103 | 0.030 |
Why?
| | Microvessels | 1 | 2016 | 66 | 0.030 |
Why?
| | Neoplasms | 1 | 2009 | 2086 | 0.030 |
Why?
| | N-Formylmethionine Leucyl-Phenylalanine | 2 | 2004 | 52 | 0.030 |
Why?
| | gag Gene Products, Human Immunodeficiency Virus | 1 | 2013 | 12 | 0.030 |
Why?
| | Receptors, Somatostatin | 1 | 2013 | 24 | 0.030 |
Why?
| | Ion Transport | 1 | 2013 | 54 | 0.030 |
Why?
| | Electric Impedance | 1 | 2013 | 100 | 0.030 |
Why?
| | Virus Activation | 1 | 2013 | 78 | 0.030 |
Why?
| | Primary Cell Culture | 1 | 2013 | 148 | 0.030 |
Why?
| | Dynamins | 1 | 2012 | 29 | 0.030 |
Why?
| | Cytosol | 1 | 2012 | 201 | 0.020 |
Why?
| | Endothelial Cells | 1 | 2016 | 677 | 0.020 |
Why?
| | Transfection | 1 | 2013 | 863 | 0.020 |
Why?
| | Male | 3 | 2014 | 55396 | 0.020 |
Why?
| | Host-Pathogen Interactions | 1 | 2013 | 295 | 0.020 |
Why?
| | Endoplasmic Reticulum | 1 | 2012 | 234 | 0.020 |
Why?
| | Cells, Cultured | 2 | 2010 | 3861 | 0.020 |
Why?
| | HEK293 Cells | 1 | 2012 | 590 | 0.020 |
Why?
| | NF-kappa B | 1 | 2013 | 636 | 0.020 |
Why?
| | Fetus | 1 | 2013 | 698 | 0.020 |
Why?
| | Time Factors | 2 | 2012 | 6077 | 0.020 |
Why?
| | Gene Expression | 1 | 2013 | 1417 | 0.020 |
Why?
| | Caspase 8 | 1 | 2005 | 43 | 0.020 |
Why?
| | Cytokines | 1 | 2013 | 1824 | 0.020 |
Why?
| | Protein Kinase C-alpha | 1 | 2005 | 41 | 0.020 |
Why?
| | Protein Kinase C-delta | 1 | 2005 | 69 | 0.020 |
Why?
| | Isoenzymes | 1 | 2005 | 283 | 0.010 |
Why?
| | Macrophage-1 Antigen | 1 | 2004 | 25 | 0.010 |
Why?
| | Androgens | 1 | 2005 | 167 | 0.010 |
Why?
| | Filipin | 1 | 2003 | 3 | 0.010 |
Why?
| | Cyclodextrins | 1 | 2003 | 8 | 0.010 |
Why?
| | Biomarkers | 1 | 2014 | 3397 | 0.010 |
Why?
| | GPI-Linked Proteins | 1 | 2003 | 54 | 0.010 |
Why?
| | CD11b Antigen | 1 | 2003 | 56 | 0.010 |
Why?
| | Leukocyte Elastase | 1 | 2003 | 71 | 0.010 |
Why?
| | Tyrosine | 1 | 2004 | 210 | 0.010 |
Why?
| | Antigens, Surface | 1 | 2003 | 146 | 0.010 |
Why?
| | Magnesium | 1 | 2003 | 144 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2003 | 145 | 0.010 |
Why?
| | Chemotaxis | 1 | 2003 | 128 | 0.010 |
Why?
| | Models, Genetic | 1 | 2005 | 559 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2003 | 164 | 0.010 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2003 | 249 | 0.010 |
Why?
| | Interleukin-8 | 1 | 2003 | 229 | 0.010 |
Why?
| | Cell Adhesion Molecules | 1 | 2003 | 167 | 0.010 |
Why?
| | Oligopeptides | 1 | 2003 | 234 | 0.010 |
Why?
| | Models, Biological | 1 | 2009 | 1611 | 0.010 |
Why?
| | Cholesterol | 1 | 2003 | 368 | 0.010 |
Why?
| | Adult | 1 | 2016 | 30375 | 0.010 |
Why?
| | Female | 1 | 2014 | 59325 | 0.000 |
Why?
|
|
Meshki's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|